Footnotes HighTouchRx has achieved a 50 Net Promoter Score (NPS).2 HighTouchRx was a Gold Award recipient at the AMCP Annual Meeting 2024, recognized for delivering an average savings of $73,142...

Managed Healthcare Executive: Prior authorization using integrated medical claims data helps diabetes patients get medications faster, with two-thirds processed automatically by July 2025 in this...

Prime Therapeutics Report shares more about single-treatment gene therapies and proper management

Oct. 29, 2025 – denosumab-desu (Jubereq) BLA approval; the 120 mg/1.7 mL single-dose vial for SC use has received FDA approval as an interchangeable biosimilar to the same presentation of denosumab...

From next-gen CFTR modulators to gene therapy and real-world drug impact, cystic fibrosis care is constantly evolving. Maryam Tabatabai, PharmD, of Prime Therapeutics, explains how innovative...

Annual meeting will feature industry research posters and educational sessions

publications Spring 2024 Prime Therapeutics Report March 15, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 6)...

The information provided has been developed based on available information as of March 3, 2025. This therapy is NOT FDA approved, and content may change as more information becomes available....